PharmaEssentia Corporation
6446
Rankning i aktier
#1413
PharmaEssentia Corporation is a biopharmaceutical firm dedicated to developing... PharmaEssentia Corporation is a biopharmaceutical firm dedicated to developing therapies for human ailments, serving both the Taiwanese and international markets. Its product portfolio prominently features Ropeginterferon alfa-2b, indicated for the management of various hematological conditions including chronic myelogenous leukemia, T-Cell leukemia, early myelofibrosis, polycythemia vera, and essential thrombocythemia. Beyond this, the company's pipeline includes TCRT, anti PD-1, PEG-cytokine X,Y, and novel checkpoint antibodies, all under development for solid tumors. A specific combination, P1101 + anti PD-1, is being explored for hepatocellular carcinoma, while PEG-GCSF addresses neutropenia. Fundamentally, its comprehensive research and development initiatives span key therapeutic areas such as hematology, infectious diseases, and oncology. Established in 1990, PharmaEssentia Corporation maintains its headquarters in Taipei, Taiwan.
Aktiekurs
$37.84
Marknadsvärde
$15.65B
Förändring (1 dag)
3.03%
Förändring (1 år)
148.76%
Land
TW
Handel PharmaEssentia Corporation (6446)
Kategori
Healthcare
Historik för aktiesplit för PharmaEssentia Corporation (6446)
Aktien PharmaEssentia Corporation (symbol: 6446) har genomgått totalt 2 aktiesplitar.
Den senaste spliten skedde den Jul 09, 2026.
En 6446-aktie köpt före Sep 11, 2025 motsvarar nu 1.229881 6446-aktier.
Den senaste spliten skedde den Jul 09, 2026.
En 6446-aktie köpt före Sep 11, 2025 motsvarar nu 1.229881 6446-aktier.
Lista över aktiesplitar
| År | Split | Multipel | Kumulativ multipel |
|---|---|---|---|
| 2026-07-09 | 1109:1000 | x1.109 | x1.229881 |
| 2025-09-11 | 1109:1000 | x1.109 | x1.109 |
Aktiesplitar för liknande företag eller konkurrenter
| Företag | Antal aktiesplitar | Kumulativ multipel | Land |
|---|---|---|---|
| 0 | - |
DE
|
|
| 0 | - |
DE
|
|
| 0 | - |
JP
|
|
| 0 | - |
CH
|
|
| 5 | x119 |
IN
|
